- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07564739
Study of Tolerance to the Application of Cold Plasma in the Treatment of Chronic Wounds (PLASMA-SAFE)
Chronic wounds affect many patients, with no downward trend in recent decades. This is a significant economic and social issue, and this condition has an impact on functional disabilities and quality of life, especially among the elderly. Diagnosis is essentially clinical, and there are many causes, but 90% of leg ulcers, for example, are primarily vascular in origin. There are wounds of traumatic, post-operative, and vascular origin, as well as pressure sores. The main purpose of invasive tests is to objectively determine the cause (arterial damage) or to check for underlying osteitis. Chronic wounds are usually infected or colonized by bacteria from the skin and digestive flora. There is no indication for antibiotic therapy in the treatment of wounds. Nursing staff play an important role in therapeutic management, which must be carried out in harmony with other healthcare professionals, such as general practitioners and specialists. This management has two main goals: to accelerate the epidermalization of chronic wounds, or even their healing, and to limit local and general complications, the recurrence of which remains the most difficult to control. There are many types of healing dressings available, adapted to each type of ulceration: fibrinous, necrotic, superinfected, etc.
Nevertheless, innovative solutions can accelerate healing, thereby reducing hospital stays, disabilities associated with chronic wounds, and complications such as skin-related septicemia. Research efforts may focus on the use of growth factors, for example, for old or stubborn forms of the disease, despite proper medical treatment, or on any other innovative technique.
The properties of cold plasma appear to be suitable for the treatment of chronic wounds, as has been demonstrated in cell models, animal models, and with argon plasma in several countries around the world on an experimental basis in humans.
The GREMI in Orléans has acquired internationally recognized expertise in the technique of cold helium plasma. The combination of this applied research laboratory and the Infectious Diseases Department of the Orléans University Hospital has led to the development of relationships that have resulted in the proposal to conduct this study, based in its first phase on the evaluation of the medical device's tolerance.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Thierry PRAZUCK, PH
- Telefonní číslo: +332 38 51 43 61
- E-mail: thierry.prazuck@chu-orleans.fr
Studijní místa
-
-
-
Orléans, Francie, 45000
- Nábor
- Centre Hospitalier Universitaire d'Orléans, France
-
Vrchní vyšetřovatel:
- Thierry PRAZUCK, MD
-
Kontakt:
- Thierry PRAZUCK, MD
- E-mail: thierry.prazuck@chu-orleans.fr
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Men or women.
- Aged 18 years or older.
- Chronic wound or ulceration.
- Wound measuring 5 to 100 cm² of arterial or venous origin.
- Evolution > 4 weeks.
- With less than 30% necrosis.
- Able to give informed written consent.
- Blood pregnancy test for women of childbearing age.
Exclusion Criteria:
- Tumor wounds
- Dialysis
- Patients requiring surgical revascularization
- Severe heart failure (NYHA III-IV) or acute myocardial infarction.
- Wounds or ulcers located less than 10 cm from the patient's airways and respiratory tract
- Severe renal failure defined as creatinine clearance <20 mL/min calculated according to the MDRD
- Patients with severe hepatic impairment (class C) according to the Child Pugh score
- Unstable liver disease (defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormality.
- Active malignant tumor
- Patients who, in the investigator's opinion, are at significant risk of suicide
- Any pre-existing physical or mental condition that may interfere with the patient's ability to comply with the administration schedule and/or protocol assessments, or that may compromise the patient's safety.
- Persons covered by Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the Public Health Code (including minors and protected adults)
- Protected person (under guardianship or curatorship)
- Person under judicial protection
- Persons deprived of their liberty
- Persons not affiliated with a social security system
- Women who are pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the study.
- Patients participating in another clinical trial evaluating a treatment
- Allergy to the dressings used in the trial
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Plasma treatment with exposure 1 min/10 cm² + conventional treatment
|
The plasma will be applied using the multi-jet probe by an investigating physician over the entire surface of the ulceration during the defined exposure times (1min/10 cm2), after which the nurse will apply the standard dressing appropriate for the characteristics of the ulceration. The sessions will be repeated daily for 8 days. |
|
Experimentální: Plasma treatment with exposure 3 min/10 cm² + conventional treatment
|
The plasma will be applied using the multi-jet probe by an investigating physician over the entire surface of the ulceration during the defined exposure times (3min/10 cm2), after which the nurse will apply the standard dressing appropriate for the characteristics of the ulceration.
|
|
Experimentální: Treatment using dressings impregnated with ions induced by exposure to plasma
|
The plasma will be applied using the multi-jet probe by an investigating physician over the dressing, after which the nurse will apply the dressing on the ulceration.
|
|
Žádný zásah: Conventional treatment with hydrocolloid dressing or adapted dressing, local care
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Level of local inflammation
Časové okno: Everyday for 8 days
|
Everyday for 8 days
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in the size of the ulcer
Časové okno: Day 0, Day 2, Day 4, Day 6 and Day 7
|
Measurement of the wound area using MolecuLight for daily photographies and computer analysis of the images
|
Day 0, Day 2, Day 4, Day 6 and Day 7
|
|
Change in the extent of tissue loss
Časové okno: Day 0, Day 2, Day 4, Day 6 and Day 7
|
Measuring wound volume with the MolecuLight
|
Day 0, Day 2, Day 4, Day 6 and Day 7
|
|
semi-quantitative change in total bacterial load
Časové okno: Day 0 and day 7
|
semi-quantitative change in total bacterial load between Day 0 and Day 7 on bacterial samples taken from the base of the ulcer
|
Day 0 and day 7
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CHUO-2024-03
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .